The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.
SMJ // Article
Original Article
Evaluation of the Effect of Biochemistry Parameters on the Clinical Course in COVID-19 Patients Who Received Tocilizumab Treatment
Abstract
Objectives: Patients who develop cytokine storm while they have coronavirus disease 2019 (COVID-19) experience more severe symptoms. This article aims to evaluate the effect of biochemical parameters on the clinical course of the disease in patients treated with tocilizumab (TCZ) due to cytokine storm.Methods: Medical documents of patients with COVID-19 were searched retrospectively. Patients who entered cytokine storm were classified as group 1 and divided into two subgroups as patients who were followed up in the ward and in the intensive care unit (ICU). Less severe COVID-19 patients who did not enter cytokine storm were included in the control group as group 2.
Results: A total of 522 patients with COVID-19 infection were included in the study. The mean age was 62.0 ± 15.6 years, and the majority were male (64.4%). Hypertension and diabetes mellitus were the two most common diseases, seen in 50.8% and 29.9%, respectively. There were 392 patients with TCZ application (group 1) and 130 patients without TCZ (group 2). Significantly higher serum glucose, magnesium, and sodium and lower calcium levels were present in group 1 than in group 2 (<0.001). Hypocalcemia, hypernatremia, hypermagnesemia, and hyperkalemia were more frequently detected in the ICU compared with the patients treated in the wards (P = 0.001, P < 0.001, P = 0.039, and P < 0.001, respectively).
Conclusions: Following up closely electrolyte disturbances may support patient survival and decrease the probability of ICU necessity. This approach should be taken before the development of important disorders to be effective in the treatment process of the main disease.
Posted in: Infectious Disease156
Full Article
Having trouble viewing the article content below? Click here to open it directly.
Images
References
1. di Filippo L, Doga M, Frara S, et al. Hypocalcemia in COVID-19: prevalence, clinical significance and therapeutic implications. Rev Endocr Metab Disord 2021;13:1–10.
2. Knorr JP, Colomy V, Mauriello CM, et al. Tocilizumab in patients with severe COVID-19: a single-center observational analysis. J Med Virol 2020;92: 2813–2820.
3. Pal R, Bhadada SK. COVID-19 and non-communicable diseases. Postgrad Med J 2020;96:429–430.
4. Martins-Filho PR, Tavares CSS, Santos VS. Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. Eur J Intern Med 2020;76:97–99.
5. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 2020;58:1131–1134.
6. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.
7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
8. Sever MY, Uzun N, Ceritli S, et al. Hyponatremia in COVID-19 patient using angiotensin type 1 receptor (AT1R) blocker and diuretic: a case report. J Res Clin Med 2020;8:22.
9. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547.
10. Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis.Aging (Albany NY) 2020;12:6049–6057.
11. Yang JK, Lin SS, Ji XJ, et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010;47:193–199.
12. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 2004;25:291–294.
13. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450–454.
14. Angelidi AM, Belanger MJ, Mantzoros CS. Commentary: COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next. Metabolism 2020;107:154245.
15. Codo AC, Davanzo GG, Monteiro LB, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysisdependent axis. Cell Metab 2020;32:437–446.e5.
16. Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, et al. COVID-19 and diabetes: a bidirectional relationship. Clin Investig Arterioscler 2021;33: 151–157.
17. Coppelli A, Giannarelli R, Aragona M, et al. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 Study. Diabetes Care 2020;43:2345–2348.
18. Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in patients With hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care 2020;43:1408–1415.
19. Schuetz P, Castro P, Shapiro NI. Diabetes and sepsis: preclinical findings and clinical relevance. Diabetes Care 2011;34:771–778.
20. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620–2629.
21. Pourfridoni M, Abbasnia SM, Shafaei F, et al. Fluid and electrolyte disturbances in COVID-19 and their complications. Biomed Res Int 2021;2021:6667047.
22. Valizadeh R, Baradaran A, Mirzazadeh A, et al. Coronavirus-nephropathy; renal involvement in COVID-19. J Renal Inj Prev 2020;9:e18.
23. Duan Y, Prasad R, Feng D, et al. Bone marrow-derived cells restore functional integrity of the gut epithelial and vascular barriers in a model of diabetes and ACE2 deficiency. Circ Res 2019;125:969–988.
24. Liu J, Han P, Wu J, et al. Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J Infect Public Health 2020;13:1224–1228. .
25. Lippi G, South AM, Henry BM. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). Ann Clin Biochem 2020;57: 262–265.
26. Sun JK, Zhang WH, Zou L, et al. Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging (Albany NY) 2020;12:11287–11295.
27. Di Filippo L, Formenti AM, Rovere-Querini P, et al. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. Endocrine 2020;68:475–478.
28. Pal R, Ram S, Zohmangaihi D, et al. High prevalence of hypocalcemia in non-severe COVID-19 patients: a retrospective case-control study. Front Med (Lausanne) 2021;7:590805.
29. Nieto-Torres JL, DeDiego ML, Verdiá-Báguena C, et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog 2014;10:e1004077.
30. Chen D, Li X, Song Q, et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China. JAMA Netw Open 2020;3:e2011122.
31. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091.
32. Noori M, Nejadghaderi SA, Sullman MJM, et al. Epidemiology, prognosis and management of potassium disorders in Covid-19. Rev Med Virol 2021; 32:e2262.
33. Moreno-P O, Leon-Ramirez JM, Fuertes-Kenneally L, et al, COVID19-ALC Research Group. Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: a case series of 306 Mediterranean patients. Int J Infect Dis 2020;100:449–454.
34. Lim JH, Jung HY, Choi JY, et al. Hypertension and electrolyte disorders in patients with COVID-19. Electrolyte Blood Press 2020;18:23–30.
35. Zhang W, Lu S, Zhang M, et al. Correlation between hyponatremia and the severity of coronavirus disease 2019. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020;32:774–778.
36. Sarvazad H, Cahngaripour SH, Eskandari Roozbahani N, et al. Evaluation of electrolyte status of sodium, potassium and magnesium, and fasting blood sugar at the initial admission of individuals with COVID-19 without underlying disease in Golestan Hospital, Kermanshah. New Microbes New Infect 2020;38:100807.
37. Trapani V, Rosanoff A, Baniasadi S, et al. The relevance of magnesium homeostasis in COVID-19. Eur J Nutr 2022;61:625–636.
38. Iotti S, Wolf F, Mazur A, et al. The COVID-19 pandemic: is there a role for magnesium? Hypotheses and perspectives. Magnes Res 2020;33:21–27.
39. Alamdari NM, Afaghi S, Rahimi FS, et al. Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran. Tohoku J Exp Med 2020;252:73–84.
40. Quilliot D, Bonsack O, Jaussaud R, et al. Dysmagnesemia in Covid-19 cohort patients: prevalence and associated factors. Magnes Res 2020;33: 114–122.
